The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)

August 2020 | Volume 19 | Issue 8 | Original Article | 703 | Copyright © August 2020

Published online July 22, 2020

M. Alan Menter MDa, Nehal N. Mehta MD MSCE FAHAb, Mark G. Lebwohl MDc, Alice B. Gottlieb MD PhDd, Alan M. Mendelsohn MDe, Stephen J. Rozzo PhDe, Craig Leonardi MDf

aDivision of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX BNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD cDepartment of Dermatology, Mount Sinai Hospital, New York, NY dDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY eSun Pharmaceutical Industries, Inc., Princeton, NJ fCentral Dermatology and Saint Louis University School of Medicine, St. Louis, MO

16. Hoffmann JH, Knoop C, Enk AH, Hadaschik EN. Routine laboratory parameter dynamics and laboratory adverse events in psoriasis patients on longterm treatment with adalimumab, etanercept, and ustekinumab. Acta Derm Venereol. 2017;97(6):705-710.
17. Hassan S, Milman U, Feld J, et al. Effects of anti-TNF-alpha treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther. 2016;18(1):261.
18. Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222-226.
19. Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2020;82(2):519-522.
20. Abbas A, Gregersen I, Holm S, et al. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015;46(3):793-799.
21. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276- 288.
22. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
23. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. Journal of Investigative Dermatology. 2012;132(3):556-562.
24. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113.
25. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clinical Rheumatology. 2014;33(6):833-839.
26. Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne). 2015;2:1.
27. Mehta NN, Shin DB, Joshi AA, et al. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. Circ Cardiovasc Imaging. 2018;11(6):e007394.
28. Brito-Luna MJ, Villanueva-Quintero DG, Sandoval-Talamantes AK, et al. Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report. Cytokine. 2016;85:130-136.


M. Alan Menter